Dronedarone

🧮 Dose calculator

Atrial fibrillation / anticoagulation · Regimen source: FDA Multaq · 2

• • Stop class I/III antiarrhythmics and strong CYP3A inhibitors before starting. Exclude pregnancy in women of reproductive potential. FDA Multaq · 2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Multaq · 8.1

  “Risk Summary MULTAQ may cause fetal harm when administered to a pregnant woman.”

• 🤱 BreastfeedingDangerous / avoid

  Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Multaq · 8.2

  “Because of the potential for serious adverse reactions in breastfed infants from MULTAQ like the adverse effects in adults, (liver injury, and pulmonary toxicity), advise patients not to breastfeed during treatment with MULTAQ and for 5 days (about 6 half-lives) after the last dose.”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. FDA Multaq · 8.4

  “Safety and efficacy in children below the age of 18 years have not been established.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Multaq · 8.5

  “More than 4500 patients with AF or AFL aged 65 years or above were included in the MULTAQ clinical program (of whom more than 2000 patients were 75 years or older).”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Multaq · 8.3

  “Contraception Advise female patients of reproductive potential to use effective contraception during treatment with MULTAQ and for 5 days after the final dose.”